GlassScriptPhysician profile
Cailee M Sanchez
NPI 1851168868
$2,884.10
in general payments reported to CMS, 2019-2025
29 companies · $918 in 2025
The $918 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,966 · 2025: $918.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,005 · Travel and Lodging: $879.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,004.64 |
| Travel and Lodging | $879.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Convatec INC. | $1,406.22 | 2024 | |
| Grifols USA, LLC | $238.38 | 2024-2025 | Prolastin-C Liquid |
| Novo Nordisk INC | $211.59 | 2024-2025 | Ozempic, Wegovy |
| Abbvie INC. | $145.33 | 2024-2025 | |
| Lundbeck LLC | $68.93 | 2024-2025 | Rexulti |
| Glaxosmithkline, LLC. | $57.43 | 2024-2025 | Trelegy Ellipta |
| Antares Pharma, INC. | $57.19 | 2024-2025 | Xyosted |
| Astrazeneca Pharmaceuticals LP | $55.49 | 2024-2025 | Airsupra, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $52.85 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $51.41 | 2024-2025 | Caplyta |
| Phathom Pharmaceuticals, INC. | $49.00 | 2024-2025 | Voquezna |
| Smith+Nephew, INC. | $46.00 | 2025 | Oasis, Collagenase Santyl |
| Otsuka America Pharmaceutical, INC. | $43.13 | 2024-2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $41.82 | 2025 | Eliquis |
| Viatris Specialty LLC | $40.03 | 2025 | Yupelri |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $37.63 | 2024-2025 | Freestyle Libre 3 |
| Radius Health, INC. | $36.11 | 2024 | Tymlos |
| Exact Sciences Corporation | $33.24 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Organogenesis INC. | $26.50 | 2025 | Apligraf |
| Axsome Therapeutics, INC. | $25.24 | 2025 | Auvelity |
| Mylan Specialty L.P. | $23.81 | 2024 | Yupelri |
| Reprise Biomedical, INC. | $20.74 | 2025 | Miro3d |
| Solventum Corporation | $19.69 | 2024 | Activ.A.C. |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.51 | 2025 | Jardiance |
| Tolmar, INC. | $16.59 | 2025 | Jatenzo |
| Aimmune Therapeutics, INC. | $15.62 | 2025 | Zenpep |
| Merck Sharp & Dohme LLC | $15.18 | 2024 | Vaxneuvance, Vaxelis, Capvaxive |
| Amgen INC. | $14.85 | 2024 | Evenity, Prolia |
| Lilly USA, LLC | $14.59 | 2024 | Zepbound, Mounjaro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cailee Sanchez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.